Quadrant Capital Group LLC Acquires 40 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Quadrant Capital Group LLC grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXXGet Rating) by 9.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 447 shares of the company’s stock after acquiring an additional 40 shares during the quarter. Quadrant Capital Group LLC’s holdings in IDEXX Laboratories were worth $244,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in IDXX. BlackRock Inc. boosted its holdings in IDEXX Laboratories by 3.4% during the 4th quarter. BlackRock Inc. now owns 8,990,586 shares of the company’s stock valued at $5,919,940,000 after acquiring an additional 296,552 shares during the period. State Street Corp lifted its position in IDEXX Laboratories by 2.6% in the fourth quarter. State Street Corp now owns 3,743,599 shares of the company’s stock valued at $2,465,010,000 after purchasing an additional 94,327 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of IDEXX Laboratories by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 1,799,521 shares of the company’s stock valued at $1,182,485,000 after purchasing an additional 31,403 shares during the period. Alliancebernstein L.P. boosted its stake in shares of IDEXX Laboratories by 18.9% during the fourth quarter. Alliancebernstein L.P. now owns 1,596,308 shares of the company’s stock valued at $1,051,105,000 after purchasing an additional 254,033 shares during the period. Finally, Capital World Investors grew its holdings in shares of IDEXX Laboratories by 0.4% in the fourth quarter. Capital World Investors now owns 994,515 shares of the company’s stock worth $654,862,000 after purchasing an additional 3,673 shares during the last quarter. 84.92% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Up 0.7 %

Shares of IDEXX Laboratories stock opened at $407.78 on Friday. IDEXX Laboratories, Inc. has a 1 year low of $318.50 and a 1 year high of $698.90. The firm has a market cap of $33.95 billion, a price-to-earnings ratio of 52.62, a PEG ratio of 5.36 and a beta of 1.14. The company has a 50-day moving average of $368.91 and a 200 day moving average of $443.56. The company has a debt-to-equity ratio of 1.68, a current ratio of 0.89 and a quick ratio of 0.81.

IDEXX Laboratories (NASDAQ:IDXXGet Rating) last released its earnings results on Wednesday, May 4th. The company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.25 by $0.02. The firm had revenue of $836.55 million during the quarter, compared to analyst estimates of $836.47 million. IDEXX Laboratories had a net margin of 20.07% and a return on equity of 104.47%. The business’s revenue was up 7.6% on a year-over-year basis. During the same period last year, the business earned $2.35 earnings per share. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 7.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on IDXX shares. Stifel Nicolaus lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating and set a $415.00 price target for the company. in a report on Wednesday. Piper Sandler dropped their price target on IDEXX Laboratories from $440.00 to $420.00 and set an “overweight” rating for the company in a research note on Tuesday, July 26th. Barclays reduced their price objective on shares of IDEXX Laboratories from $700.00 to $582.00 and set an “overweight” rating on the stock in a research report on Friday. Bank of America cut shares of IDEXX Laboratories from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $550.00 to $470.00 in a research report on Thursday, May 5th. Finally, The Goldman Sachs Group upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and reduced their price target for the company from $530.00 to $435.00 in a research report on Thursday, July 21st. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $519.38.

IDEXX Laboratories Company Profile

(Get Rating)

IDEXX Laboratories, Inc develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.

Featured Articles

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXGet Rating).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.